RESPONSE OF DEBTORS TO THE REPORTS OF ERIC M....
Transcript of RESPONSE OF DEBTORS TO THE REPORTS OF ERIC M....
1
IN THE UNITED STATES BANKRUPTCY COURTFOR THE EASTERN DISRICT OF PENNSYLVANIA
In Re:
KidsPeace Corporation, et. al.1
Debtors.
Chapter 11
Jointly Administered
Case No. 13-14508 (REF)
RESPONSE OF DEBTORS TO THE REPORTS OF ERIC M. HUEBSCHER ANDHUEBSCHER & CO. AS PATIENT CARE OMBUDSMAN OF THE DEBTORS
In the PCO’s Supplemental Report, the PCO reported about a Letter2 that the PCO
became aware of that was authored by a Mental Health Technician and signed by other
employees of the Debtors. It is the Debtors’ understanding that PCO reported the Letter to the
Department of Public Welfare on or about November 7, 2013 as a complaint. As a result, on
November 20, 2013, the Department of Public Welfare Office of Mental Health and Substance
Abuse Services (“OMHSAS”) conducted a survey of the Hospital to examine the following areas
of concern:
1. Increased Client Acuity Levels;
2. Food Shortages;
3. Excessive Use of Restraints and Isolation;
4. High Staff Turnover and Staff Vacancies;
5. Consumers Sleeping on the Floor;
6. Inappropriate Staffing Ratios; and
1 The Debtors and the last four digits of their respective taxpayer identification numbers are as follows:KidsPeace Corporation (3394); KidsPeace Children’s Hospital, Inc. (4910); KidsPeace Mesabi Academy, Inc. (4179); KidsPeace NationalCenters, Inc. (4908); KidsPeace National Centers of Georgia, Inc. (7440); KidsPeace National Centers of New England, Inc. (1326); KidsPeaceNational Centers of North America, Inc. (4765); Iron Range School, Inc. (0561); and KidsPeace National Centers of New York, Inc. (1888). TheDebtors’ address is 5300 KidsPeace Drive, Orefield, Pennsylvania 18069. References in this report to the Debtors refer to at least one of theDebtor entities.
2Defined on page 3 of 8 in the PCO’s Supplemental and Special Report
Case 13-14508-ref Doc 722 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Main Document Page 1 of 2
2
7. Inadequate Staff Orientation.
In a letter dated December 18, 2013 (attached hereto as Exhibit A), OMHSAS informed
the Debtors of their findings and indicated that there were “No deficiencies…identified at the
time of the visit.”
Upon review of the PCO’s Reports and Responses by the Debtor, the Board of Directors
of the Debtors directed management to engage an independent reviewer to conduct an
assessment of its health care operations in Pennsylvania. The PCO made a similar
recommendation to the Debtors. The Debtors engaged such an individual, Dr. Oscar Bukstein.
Dr. Bukstein’s completed an Independent Review and submitted the review to Debtors on
December 17, 2013 (attached hereto as Exhibit B).
Respectfully submitted,
KIDSPEACE CORPORATION
By: /s/ William IsemannDate: January 9, 2013 WILLIAM ISEMANN
Case 13-14508-ref Doc 722 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Main Document Page 2 of 2
Case 13-14508-ref Doc 722-1 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit A Page 1 of 2
Case 13-14508-ref Doc 722-1 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit A Page 2 of 2
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 1 of 32
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 2 of 32
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 3 of 32
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 4 of 32
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 5 of 32
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 6 of 32
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 7 of 32
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 8 of 32
Revised November 16, 2013
1
CURRICULUM VITAE
I. General Biographical Information
A. Personal
1. Name: Oscar Gary Bukstein, M.D.
2. Citizenship: United States of America
3. Education:
a. UNDERGRADUATE:
Washington University 9/1972-5/1974
St. Louis, Missouri
University of Missouri 6/1974-5/1976
Bachelor of Arts, Philosophy, 1976
Columbia, Missouri
b. GRADUATE:
University of Texas 8/1978-6/1980
School of Public Health Masters in Public Health (MPH) 1980
Houston, Texas
University of Texas 8/1979-5/1983
Medical Branch Doctor of Medicine (MD), 1983
Galveston, Texas
c. POST GRADUATE:
Psychiatry Internship 6/1983-6/1984
Western Psychiatric Institute and Clinic
University of Pittsburgh
Pittsburgh, Pennsylvania
Combined Residency 7/1984-6/ 1988
and Fellowship in General and Western Psychiatric Institute and Clinic
Child/Adolescent Psychiatry University of Pittsburgh,
Pittsburgh, Pennsylvania
B. Academic Appointments:
1. Current Visiting Professor of Psychiatry 10/2010- present
Director, Division of Child and Adolescent Psychiatry
Department of Psychiatry and Behavioral Sciences
The University of Texas Medical School at Houston
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 9 of 32
Revised November 16, 2013
2
2. Previous ACADEMIC APPOINTMENTS
Assistant Professor 7/1988- 6/1997
Department of Psychiatry
Western Psychiatric Institute and Clinic/ University of Pittsburgh
Pittsburgh, PA
Associate Professor 6/1997- 4/2009
Department of Psychiatry
Western Psychiatric Institute and Clinic
University of Pittsburgh School of Medicine
Professor of Psychiatry 4/2009-10/2010
Department of Psychiatry
Western Psychiatric Institute and Clinic
University of Pittsburgh School of Medicine
Pittsburgh, PA
Adjunct Professor of Psychiatry 10/2010-present
Western Psychiatric Institute and Clinic
University of Pittsburgh School of Medicine
Pittsburgh, PA
C. Other Advanced Training
NIMH Post-Doctoral Fellowship in Clinical. 7/1987-6/1988
Research Training in Psychiatry
Western Psychiatric Institute and Clinic/University of Pittsburgh
Pittsburgh, Pennsylvania
D. Other Information
1. HONORS & AWARDS
a. Hamilton F. Ford Award for Psychiatry in Medicine 1983
University of Texas Medical Branch
b. American Psychiatric Association/Mead Johnson Fellow 1985-1986
c. American Academy of Child and Adolescent Psychiatry
d. Outstanding Mentor Award - American Academy of Child and 2005, 2008
Adolescent Psychiatry
F, Dean’s Teaching Excellence Award
University of Texas Health Science Center 2011-2012
2. Board Certification
American Board of Psychiatry and Neurology (ABPN):
Board Certification - General Psychiatry, No. 33073 1990
Board Certification - Child and Adolescent Psychiatry, No 2725 1991
Board Certification - Addiction Psychiatry, No. 064 1993,
2003
3. Other Non-Academic positions
Medical Director, Adolescent Drug Abuse 8/1989-8/1992
& Psychiatric Treatment Program
Western Psychiatric Institute and Clinic
Pittsburgh, PA
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 10 of 32
Revised November 16, 2013
3
Medical Director, Pittsburgh Adolescent 9/1990-8/2000
Alcohol Research Center (PAARC)
Western Psychiatric Institute and Clinic/University of Pittsburgh
Pittsburgh, PA
Medical Director, Child and Parent Behavior Clinic: 9/1992-5/1997
Outpatient & Partial Hospitalization
Western Psychiatric Institute and Clinic
Pittsburgh, PA
Medical Director, Attention Deficit Disorder Clinic 8/1993-9/2010
and Research Program
Western Psychiatric Institute and Clinic
University of Pittsburgh School of Medicine
Pittsburgh, PA
Medical Director, Chronic Disorders 8/1995-6/2004
Treatment & Intervention Service (CACTIS)
Western Psychiatric Institute and Clinic
Pittsburgh, PA
Director, Clinical Core, Pittsburgh Adolescent 9/1998 –8/2001
Alcohol Research Center (PAARC)
Western Psychiatric Institute and Clinic
University of Pittsburgh School of Medicine
Pittsburgh, PA
Medical Director, Adolescent Substance Abuse 10/2003-10/2010
Treatment Program
Western Psychiatric Institute and Clinic
Pittsburgh, PA
Medical Director, Appalachian Tri-State Node 9/2005-10/2010
NIDA Clinical Trials Network
Western Psychiatric Institute and Clinic
Pittsburgh, PA
Staff Psychiatrist 2/2011-7/2013
Harris County Psychiatric Center
Houston, Texas
Director 6/2012-5/2013
UT Pediatric Bipolar Clinical Research Program
Houston, Texas
Changing Lives through Autism Spectrum Services 1/2011-7/2013
University of Texas Health Science Center
Houston, Texas
Medical Director 7/2013 – present
DePelchin Children’s Center
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 11 of 32
Revised November 16, 2013
4
Houston, Texas
II Research Information
R01 MH Stimulant & Risperidone for Youth Co- Investigator 2008- NIMH
077676-01A2 with Severe Physical Aggression 10% effort 2012 $1,930,751
5R01HD Reading ICARD: Intervention Co-investigator 2010 $887,097
060617-02 for Children with Attention 10% effort 2014
and Reading Disorders
86-1063-86 Adolescent Suicide and Suicidal
Behavior
Interviewer
Training
1987-
88
WT Grant
Foundation
N/A Assessment of Personality in
Adolescents
Interviewer 1987-
88
MHCRC Pilot
Funding
N/A Affective Disorders and Substance
Abuse in Adolescents
Principal
Investigator
1989-
90
MHCRC Pilot
Funding
DA-05605-04 Drug Abuse Vulnerability:
Mechanisms and Manifestations –
Clinical Research Center
Training 1989-
94
NIDA
AA-08284-05 Alcohol Use Among Teenagers and
Infant Outcome
Co-Investigator 1989-
94
NIAAA
AA-05952-04 Adolescent Alcohol Abuse: Clinical
Research Center
Co-Investigator 1990-
95
NIAAA
MH 50467 Multi-Modal Treatment Study of
Attention-Deficit Hyperactivity
Disorder
Co-Investigator 1993-
98
NIMH
N/A Services needs and Concerns Co-Investigator 1994-
96
Mental Health
Research Center
AA-08746 Adolescent Alcohol Abuse:
Biobehavioral Manifestations- Clinical
Research Center
Co-Investigator 1995-
2000
NIAAA
N/A Double Blind, Fixed-Dose Study of
Transdermal Buspirone in ADHD
Principal
Investigator
1997-
98
Bristol-Myers
Squibb
N/A Screening, Initiation, Safety and
Efficacy of OROS (Methylphenidate)
Principal
Investigator
1998-
2000
ALZA Corp
MH57727 Effectiveness of Community Services
for Conduct Problems
Co-Investigator 1998-
2003
NIMH
N/A Treatment for Juvenile Sex Offenders Co-Investigator 1998-
2004
PA Commission
on Crime and
Delinquency
N/A Development and Outcomes of a Dual
Diagnosis Treatment Program for
Delinquent Youth
Principal
Investigator
2000-
04
PA Commission
on Crime and
Delinquency
K08 00280AA
Alcohol and Mental Disorders Among
ED-Treated Adolescents
Co-Investigator
2000-
05
NIAAA
N/A An Evaluation of the Safety and
Efficacy of CONCERTATM
(up to
72mg daily) in Adolescents with
ADHD
Principal
Investigator
2001-
02
McNeil
Pharmaceuticals
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 12 of 32
Revised November 16, 2013
5
N/A
A Multicenter, Double-Blind Placebo-
Controlled, Safety and Efficacy Study
of Methylphenidate Transdermal
System in Pediatric Patients with
ADHD
Principal
Investigator
2001-
02
Noven
Pharmaceuticals
AA013370-01 Pharmacological Intervention for
Adolescents with Major Depressive
Disorder and Alcohol Use Disorders
Co-Investigator 2001-
05
NIAAA
AA000301 K-24: Psychopharmacology of
Adolescents with ADHD and Alcohol
use Disorders
Principal
Investigator
2001-
07
NIAAA
NS39087 Clonidine in ADHD Treatment &
Preschool Supplement
Co-Investigator 2002-
06
MH65420 In Vivo 31P Spectroscopy & MRI in
ADHD
Co-Investigator 2003-
06
NIMH
R21 DA
16631-03
Home-based Behavioral Therapy
(HBT): Psychosocial Intervention
Project for Early Adolescents with
Pre- or Early Substance Use Disorder
Principal
Investigator
2003-
08
NIDA
R01 MH
57727-09
Enhancing Long-Term Outcome in
Childhood Behavior Disorder
Co-Investigator 2003-
08
NIMH
N/A A Phase III Double-Blind, Multicenter,
Placebo-controlled Study to Evaluate
the Safety and Efficacy of
Methylphenidate Transdermal
System® (MTS) vs. CONCERTA
® in
Pediatric Patients aged 6-12 with
ADHD
Principal
Investigator
2004-
05
Shire
Pharmaceuticals
MH66775 Treatment of Adolescent Suicide
Attempters Study (TASA)
Principal
Investigator
2004-
07
NIMH
DA019142-01 Fluoxitine for MDD and Cannabis
Disorder in Young People
Co-Investigator
(10%)
2004-
08
NIDA
$340,859
N/A ADHD in a Detention Center
Population
Principal
Investigator
2005-
06
NIMH
DA020036-01
Clinical Trial Network: Appalachian
Tri-State Node
Co-Investigator
Medical
Director
(27.5%)
2005-
10
NIDA
$1,232,345
CTN 0028 Osmotic-Release Methylphenidate
(OROS MPH) for ADHD in
Adolescents with Substance Use
Disorder
Principal
Investigator
(site)
2006-
08
NIDA
AA016482 Northwestern Pennsylvania
Adolescent Alcohol Research
Cooperative
Co-Investigator
(10%)
2006-
09
NIAAA
$187,045
N/A A Double-Blind, Randomized,
Multicenter, Flexible-Dose Study
Evaluating the Efficacy and Safety of
SPD509 in Children Aged 6-12 with
Symptoms of Oppositionality and a
Principal
Investigator
2007-
08
Shire
Pharmaceuticals
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 13 of 32
Revised November 16, 2013
6
Diagnosis of ADHD
N/A Family Focused Treatment for
Adolescents with Bipolar Disorder and
Substance Use Disorders
Co-Investigator
Mentor
(5%)
2007-
09
NARSAD
$60,000
N/A Association Between Substance Use
and Suicidality among Adolescents
with Bipolar
Co-Investigator
(5%)
2008-
09
American
Foundation for
Suicide
Prevention
N/A A Phase III, Double-Blind,
Randomized, Placebo-Controlled,
Multicenter, Dose Optimization Study
Evaluating the Efficacy and Safety of
SPD503 in Combination with
Psychostimulants in Children and
Adolescents aged 6-17 Years with a
Diagnosis of Attention
Deficit/Hyperactivity Disorder
(ADHD)
Principal
Investigator
2008-
10
Shire
Pharmaceuticals
R01MH
007676-01A2
Stimulant & Risperidone for Youth
with Severe Physical Aggression
Principal
Investigator
(30%)
2008-
12
NIMH
$1,930,751
R01 DA
012414-06
Development of Drug Abuse in ADHD
Adolescents
Co-Investigator
(5%)
2008-
13
NIDA
$218,419
N/A A Placebo-Controlled, Double-blind,
Parallel-group, Individualized Dosing
Study Optimizing Treatment of Adults
with ADHD to an Effective Response
with OROS® Methylphenidate
Principal
Investigator
2009-
10
McNeil
Pharmaceuticals
N/A A Phase III, Double-blind,
Randomized, Multicenter, Placebo-
controlled, Dose Optimization Study
Evaluating the Tolerability and
Efficacy of AM/PM Daily Dosing with
Extended-release Guanfacine
Hydrochloride in Children Aged 6-12
with a Diagnosis of ADHD
Principal
Investigator
2009-
10
Shire
Pharmaceuticals
B. National Scientific Participation:
1. Journal editorial boards
Journal of Child and Adolescent Substance Abuse 2000- Present
Journal of the American Academy of Child and Adolescent Psychiatry 2002-2007
Journal of ADHD and Related Disorders 2008- 2011
2. Review panels
a. NIAAA Special Emphasis Panel: Research In Medical Settings, 2002
b. National Institute on Drug Abuse (NIDA), Clin Trials Network, 2004-2005
c. NIDA Workgroup, Design Clinical Trials Network Study 2005
on Pharmacologic Treatment of Substance Use Disorder in ADHD
d. NIMH/NIH Loan Repayment Program, 2006-present
e. NIMH Mental Health Services IRG, ad hoc 2006-2007
f. Psychiatry Core Group, NICHD Workshop on Advancing 2012
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 14 of 32
Revised November 16, 2013
7
Pediatric Therapeutics,
3. Professional societies, elected positions.
American Psychiatric Association 1983-Present
Workgroup on Substance Abuse Practice Guidelines 1992-1995
Council on Addiction Psychiatry 2010-Present
American Academy of Child and Adolescent Psychiatry 1984-Present
Substance Abuse Committee 1991-1998
Workgroup on Quality Issues 1996-Present
Co-Chair, Workgroup on Quality Issues 2004-Present
Pediatric Psychopharmacology Initiative (PPI) 2006-present
E-AACAP Advisory Group 2007-2011
American Academy of Addiction Psychiatry 1989
American Society of Addiction Medicine 1992-2005
International Society on Research in Child and 1997-Present
Adolescent Psychopathology
Research Society on Alcoholism 1999-Present
Texas Society of Child and Adolescent Psychiatry 2010-Present
Harris County Medical Society 2011-Present
4. Invited lectures, presentations, research seminars: National, International
October 19, 1989 Bukstein O, Kaminer Y: Administrative and treatment issues in a program for
dual-diagnosis adolescents. The 36th Annual Meeting of the American
Academy of Child and Adolescent Psychiatry, New York, NY.
October 19, 1991 Bukstein OG: New Diagnostic Instruments for Adolescent Chemical
Dependency Assessment, Symposium, Annual Meeting of American Academy
of Child and Adolescent Psychiatry, San Francisco, CA.
October 18, 1995 Bukstein OG: Mood Disorders and Adolescent Substance Use Disorders.
Institute sponsored by NIDA, Annual Meeting of the American Academy of
Child and Adolescent Psychiatry, New Orleans, LA.
October 19, 1995 Bukstein OG, Clark DB, Pollock N, Lynch K: Mood, Conduct Disorder and
Substance Abuse in Adolescents. Symposium presented at the Annual Meeting
of the American Academy of Child and Adolescent Psychiatry, New Orleans,
LA.
October 25, 1996 Bukstein OG, Clark DB, Pollock N, Lynch K: Adolescents with Alcohol and
Other Substance Use Disorders Only: A Description and Comparison with
Adolescents with Comorbidity, Symposium presented at Annual Meeting of the
American Academy of Child and Adolescent Psychiatry, Philadelphia, PA
October 27, 2001 Bukstein OG, Clark DB, Kelly T, Lynch K: The Effects of Psychiatric
Comorbidity on Substance Use Variables In Adolescents With Alcohol Use
Disorders. Symposium, Annual Meeting of American Academy of Child and
Adolescent Psychiatry, Honolulu, Hawaii.
April 30, 2001 Bukstein OG: Treatment Innovations in Adolescent Substance Use Disorders,
Symposia, Promised Childhood Congress, Israeli Association of Child and
Adolescent Psychiatry, Tel Aviv, Israel
May 3, 2001 Bukstein OG: Pharmacotherapy of Mood Disorders and Substance Use
Disorders in Adolescents, Symposia, Promised Childhood Congress, Israeli
Association of Child and Adolescent Psychiatry, Tel Aviv, Israel
October 24, 2002 Bukstein OG, Cornelius J, Mezzich A, Wood S: Major Depressive Disorder in
Female Adolescents With and Without Alcohol Use Disorder, Symposium,
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 15 of 32
Revised November 16, 2013
8
Annual Meeting of American Academy of Child and Adolescent Psychiatry, San
Francisco, CA
October 25, 2002 Bukstein OG, Molina B. Clark DB, Wood, S: Substance Abuse Comorbidity with
ADHD, Symposium, Annual Meeting of American Academy of Child and
Adolescent Psychiatry, San Francisco, CA
October 18, 2003 Bukstein OG: Recent Advances in Adolescents Substance Use Disorders,
Symposium, Annual Meeting of American Academy of Child and Adolescent
Psychiatry, Miami, FL
October 23, 2004 Bukstein OG, Clark DB, Cornelius J, Mezzich A, Wood S: ADHD and CD
Symptoms Affect the Course of Alcohol Use Disorders in Adolescents,
Symposium, Annual Meeting of American Academy of Child and Adolescent
Psychiatry, Washington, DC
March 23, 2005 Bukstein OG: Psychopharmacology of Adolescent Substance Use Disorders,
Symposium presented at 2005 Joint Meeting on Adolescent Treatment
Effectiveness, DHHS, Washington, DC
October 22, 2005 Bukstein OG: Recent Findings in Adolescent Substance Abuse Treatment
Research Symposium. Annual Meeting of American Academy of Child and
Adolescent Psychiatry, Toronto, Ontario Canada
October 27, 2006 Bukstein OG, Christian N, Baker J, Molina BS: ADHD in a Juvenile Detention
Center Population Symposium. Annual Meeting of American Academy of Child
and Adolescent Psychiatry, San Diego, CA,
October 28, 2006 Bukstein OG, Molina BS, Kelly T, Wood S: Patterns of Delinquent Behavior in
Adolescents with Alcohol Use Disorders. Symposium. Annual Meeting of
American Academy of Child and Adolescent Psychiatry, San Diego, CA
November 2006 Molina BSG, Flory K, Bukstein O, Greiner A, Baker J, Evans SW: Feasibility
of a randomized study of the CHP model of treatment for ADHD in a large
Pittsburgh middle school. In S.W. Evans (Chair), School-based treatment of
middle school aged children with ADHD. Symposium presentation at the
Annual Meeting of the Association for Behavioral and Cognitive Therapy,
Chicago, IL.
October 27, 2007 Bukstein OG: Substance Use Disorders among Adolescents with Bipolar
Disorder. Symposium. Annual Meeting of American Academy of Child and
Adolescent Psychiatry, Boston, MA.
May 5, 2008 Bukstein OG: Mental Health and Substance Use Treatment Utilization in
Adolescents with Substance Use Disorders. Symposium. Annual Meeting of the
American Psychiatric Association, Washington, DC.
October 29, 2008 Bukstein OG: Depression and Substance Use Disorders in Adolescents,
Institute. Annual Meeting of American Academy of Child and Adolescent
Psychiatry, Chicago, LI.
November 1, 2008 Bukstein, OG: Assessment, Coordination of Care, and clinical considerations in
the Management of Substance Use Disorders in Adolescents. Annual Meeting of
American Academy of Child and Adolescent Psychiatry, Chicago, IL.
June 20, 2009 Bukstein, OG: Depression and Alcohol Use in Adolescents: A Longitudinal
Examination. Symposium Meeting of the International Society for Research in
Child and Adolescent Psychopathology. Seattle, WA.
October 29, 2009 Bukstein, OG: Medication Acceptability and Effectiveness in Oppositional
Defiant Disorder/Conduct Disorder Children with Comorbid ADHD.
Symposium. Annual Meeting of American Academy of Child and Adolescent
Psychiatry. Honolulu, HI
October 29, 2009 Bukstein, OG: Current Perspectives on Integrated Psychosocial Interventions
for Adolescents with Comorbid Mood-Related and Substance Use Disorders.
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 16 of 32
Revised November 16, 2013
9
Symposium. Annual Meeting of American Academy of Child and Adolescent
Psychiatry. Honolulu, HI
October 30, 2010 Bukstein, OG: Assessment and Treatment of Alcohol and Drug Problems in
College Symposium. Annual Meeting of American Academy of Child and
Adolescent Psychiatry. New York City, NY
October 20, 2011 Bukstein, OG Substance Use Disorders in Adolescents. AACAP Life Long
Learning Institute, Annual Meeting of American Academy of Child and
Adolescent Psychiatry. Toronto, ON, Canada
February 10, 2012 Bukstein, OG Substance Use Disorders in Adolescents. AACAP Life Long
Learning Institute, Sand Diego, CA.
October 28, 2012 Bukstein, OG: Assessment and Treatment of Alcohol and Drug Problems in
College Symposium. Annual Meeting of American Academy of Child and
Adolescent Psychiatry. San Francisco, CA
October 27 , 2013 Treatment of Severe Child Aggression: TOSCA Network. Symposium. Annual
Meeting of American Academy of Child and Adolescent Psychiatry. Orlando,
FL.
Invited Lectures:
October 26, 1990 Patterns of Affective Comorbidity in a Clinical Population of Adolescent
Substance Abusers, NIMH Conference on Dual Diagnosis, Rockville, MD.
July 14, 1991 Adolescent Conduct Disorder and Substance Abuse, Expert Panel Conference,
Value Behavioral Health, Santa Monica, CA.
March 28, 1996 Risk Factors for Substance Use Disorders in Children and Adolescents. Hospital
for Sick Children, Toronto, Canada.
March 29, 1996 Mood and Conduct Disorders in Adolescents with Substance Use Disorders.
Clarke Institute and Addiction Research Foundation, Toronto, Canada.
November 5-6, 1996 Adolescent Substance Abuse, Mid-Missouri Mental Health Center, University of
Missouri School of Medicine, Columbia, MO.
May 15, 1997 Adolescent Substance Abusers and Coexisting Psychiatric Disorders, Annual
Meeting of Missouri Chemical Dependency Professionals, Osage Beach, MO.
May 12, 1998 Comorbidity in Adolescents with Substance Use Disorders, Comprehensive
Drug and Alcohol Program of Fairfax County, Fairfax, VA.
November 3, 4, 1998 Comorbidity in Adolescents with Substance Use Disorders, Department of
Drug and Alcohol, State of Vermont, Burlington, VT.
November 19, 1998 Salient Variables for Adolescent Treatment Research, National Institute on
Alcohol Abuse and Alcoholism, Bethesda, MD.
March 20, 1999 Treatment Update: What’s New in the Treatment of Adolescent Substance
Abuse, Indiana Psychiatric Society, Indianapolis, IN.
June 2, 2000 Dual Diagnosis in Adolescents, Delaware Department of Public Welfare, Dover,
DE.
February 5, 2001 Attention Deficit Hyperactivity and Substance Use Disorders, Grand Rounds,
Department of Psychiatry, University of Miami, FL.
October 12, 2001 Psychopharmacology of Adolescents With Substance Use Disorders: Using
Diagnosis Specific Treatments. Treating adolescent substance abuse; The state
of the science. A NIDA sponsored conference. Center for Treatment Research
on Adolescent Drug Abuse, University of Miami. Coral Gables, FL.
January 8, 2002 Attention Deficit Hyperactivity Disorder and Substance Abuse in Adolescents:
Risk Factors and Treatment Targets. Fisher-Cummings Visiting Professorship in
Substance Abuse, Children’s Hospital of Michigan, Detroit, MI.
August 1, 2003 Adolescent Substance Abuse and ADHD, Grand Rounds, Department of Psychiatry,
University of South Florida, Tampa, FL.
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 17 of 32
Revised November 16, 2013
10
March 4, 2004 Substance Abuse Comorbidity with ADHD. Grand Rounds, University of
Minnesota, Minneapolis, MN.
September 30, 2004 Adolescent Substance Use Disorders and Comorbidity, Annual Kentucky Mental
Health Institute, Louisville, KY.
February 25, 2005 Adolescent Substance Use Disorders, Annual Review, American Academy of
Addiction Psychiatry, Atlanta, GA.
October 18, 2005 Clinical Practice Guidelines, Research Forum. Annual Meeting of American
Academy of Child and Adolescent Psychiatry, Toronto, Ontario, Canada.
April 13, 2006 ADHD Medical Safety, Grand Rounds, Allegheny General Hospital, Pittsburgh,
PA..
November 19, 2007 Does Dual Diagnosis Matter?, Children’s Hospital Research Institute. Children’s
Hospital of Columbus, Columbus, OH.
November 20, 2007 What Really is Dual Diagnosis Treatment for Adolescents? Alcohol, Drug and
Mental Health Board and The Ohio State University’s Lecture Series. Alcohol,
Drug and Mental Health Board of Franklin County, Columbus, OH.
July 28, 2010 Best Practices for the Assessment and Treatment of Children and Adolescents
with Substance Use Disorders. Annual Meeting of the Texas Society of Child
and Adolescent Psychiatry, Galveston, TX
March 9, 2011 The Development of Practice Parameters for the Assessment and Treatment of
Children and Adolescents with Substance Use Disorders, Grand Rounds, Boston
Children’s Hospital, Boston, MA
January 20, 2012 Treatment of Adolescent Substance Use Disorders: State of the Science, Grand
Rounds, Department of Psychiatry, Case Western Reserve University, Cleveland,
OH
May 3, 2013 Adolescent Dual Disorders: Does It Make a Difference. Florida International
University, Miami, FL
November 20, 2013 Treatment of Severe Child Aggression: Findings from the TOSCA Network.
Grand Rounds. University of Texas Health Science Center. Houston, TX
C. Publications
Full Papers: Refereed Articles:
1. Bukstein OG, Brent DA, Kaminer Y: Comorbidity of substance abuse and other psychiatric
disorders in adolescents. Am J Psychiatry, 146:1131-1141, 1989.
2. Kaminer Y, Bukstein OG: Adolescent Chemical Use and Dependency: Current issues in
epidemiology treatment and prevention. ACTA Psychiatrica Scand, Vol. 79:415-424, 1989.
3. Brent DA, Zelenak JP, Bukstein OG, Brown RV: Reliability and validity of the structured
interview for personality disorders in adolescents. J Am Acad Child Adol Psychiatry, 29:349-
354, 1990.
4. Tarter RE, Laird B, Kabene M, Bukstein OG, Kaminer Y: Drug abuse severity in adolescents
is associated with magnitude of deviation in temperament traits. Br J Addict, 85:1501-1504,
1990.
5. Kaminer Y, Bukstein OG, Tarter RE: The Teen-Addiction Severity Index: Rationale and
reliability. Int J Addictions, 26:219-226, 1991.
6. Arria A, Mezzich A, Tarter R, Bukstein O, Van Hasselt V, Van Thiel D: Evidence for early
onset liver injury in alcohol abusing adolescents. Alcohol Clin Exp Res, 15:371, 1991.
7. Tarter RE, Laird S, Bukstein O: Multivariate comparison of adolescent offspring of substance
abuse parents: Community and treatment samples. J Subst Abuse, 3:301-306, 1991.
8. Bukstein OG, Glancy LJ, Kaminer Y: Patterns of affective comorbidity in a clinical
population of dually-diagnosed adolescent substance abusers. J Am Acad Child Adol
Psychiatry, 6:1041-1045, 1992.
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 18 of 32
Revised November 16, 2013
11
9. Kaminer Y, Tarter RE, Bukstein OG, Kabene M: Comparison between treatment completers
and noncompleters among dually diagnosed substance abusing adolescents. J Am Acad Child
Adol Psychiatry, 31:1046-1049, 1992.
10. Tarter RE, Laird SB, Bukstein OG, Kaminer Y: Validation of the adolescent drug use
screening inventory: Preliminary findings. Psychol Addict Behav, 6:233-236, 1992.
11. Van Hasselt VB, Ammerman RT, Glancy LJ, Bukstein OG: Maltreatment in psychiatrically
hospitalized dually-diagnosed adolescent substance abusers. J Am Acad Child Adol
Psychiatry, 31:868-874, 1992.
12. Van Hasselt VB, Hersen M, Null JA, Ammerman RT, Bukstein OG, McGillivray J, Hunter A:
Drug abuse prevention for high-risk African-American children and their families: A review
and model program. Addict Behav, 18:213-234, 1993.
13. Bukstein OG, Brent DA, Perper JA, Moritz G, Baugher M, Schweers J, Roth C, Balach L:
Risk factors for completed suicide among adolescents with a lifetime history of substance
abuse: A case-control study. Acta Psychiatrica Scandinavica, 88:403-408, 1993.
14. Van Hasselt VB, Null JA, Kempton T, Bukstein OG: Social skills and depression in
adolescent substance abusers. Addict Behav, 18:9-18, 1993.
15. Martin CS, Arria AM, Mezzich AC, Bukstein OG: Patterns of polydrug use in adolescent
alcohol abusers. Am J Drug Alcohol Abuse, 19:511-521, 1993.
16. Bukstein OG: The treatment of adolescent alcohol abuse and dependence. Alcohol Health
and Research World, 18:296-301, 1994.
17. Bukstein OG, Kaminer Y: The nosology of adolescent substance abuse. Am J Addict, 3:1-13,
1994.
18. Messer SC, Kempton T, Van Hasselt VB, Null JA, Bukstein OG:. Cognitive distortions and
adolescent affective disorder: Validation of the CNCEQ in an inpatient sample. Behav Modif,
18:339-351, 1994.
19. Kempton T, Van Hasselt VB, Bukstein OG, Null JA: Cognitive distortions and psychiatric
diagnosis in dually diagnosed adolescents. J Am Acad Child Adol Psychiatry, 33:217-2322,
1994.
20. Leonard HL, Topol D, Bukstein O, Hindmarsh D, Allen AJ, Swedo SE: Clonazepam as an
augmenting agent in the treatment of childhood-onset Obsessive-Compulsive Disorder. J Am
Acad Child Adol Psychiatry, 33:792-794, 1994.
21. Arria AM, Dohey MA, Mezzich AC, Bukstein OG: Self-reported health problems and
physical symptomology in adolescent alcohol abusers. J Adol Health, 16:226-231, 1995.
22. Bukstein OG: Influences on the risk and course of substance use and abuse in adolescents.
Current Opinion in Psychiatry, 8:218-221, 1995.
23. Clark DB, Bukstein OG, Smith MG, Kaczynski NA, Mezzich AC, Donovan JE: Identifying
anxiety disorders in adolescents hospitalized for alcohol abuse or dependence. Psychiatric
Services, 46:618-620, 1995.
24. Martin CS, Kaczynski NA, Maisto SA, Bukstein OG, Moss HB: Patterns of alcohol abuse
and dependence symptoms in adolescent drinkers. J Stud Alcohol Drugs, 56:672-680, 1995.
25. Bukstein OG: Aggression, violence and adolescent substance abuse. Child Adolesc Psychiatr
Clin N Am, 5:93-109, 1996.
26. Clark DB, Pollack N, Bukstein OG, Mezzich AC, Bromberger JT, Donovan JE: Gender and
comorbid psychopathology in adolescents with alcohol dependence. J Am Acad Child Adol
Psychiatry, 36:1195-1203, 1997.
27. American Academy of Child and Adolescent Psychiatry, Primary author: Bukstein OG:
Practice parameters for the assessment and treatment of children and adolescents with
substance use disorders. J Am Acad Child Adol Psychiatry, 36(Supl):140S-156S, 1997.
28. Dulcan, M, Dunne, JE, Ayres, W, Arnold, V, Benson, RS, Bernet, W, Bukstein, O, Kinlan, J,
Leonard, H, Licamele, W, McClellan, J, Sloan, LE, Miles, CM. Practice parameters for the
assessment and treatment of children, adolescents, and adults with Attention-
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 19 of 32
Revised November 16, 2013
12
Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 36(Supl):85S-121S,
1997.
29. American Academy of Child and Adolescent Psychiatry, Primary author: Bukstein OG:
Summary of the practice parameters for the assessment and treatment of children and
adolescents with substance use disorders. J Am Acad Child Adol Psychiatry, 37:122-126,
1998.
30. Smith B, Pelham WE, Evan S, Gnagy E, Molina B, Bukstein OG, Grenier A, Myak C,
Presnell M, Willoughby M: Dosage effects of methylphenidate on the social behavior of
adolescents with attention-deficit hyperactivity disorder. Exper Clin Psychopharmacol, 6:187-
204, 1998.
31. Bukstein OG, Kolko DJ: The effects of methylphenidate on aggressive, urban children with
attention-hyperactivity disorder. J Clin Child Psychol, 27:340-351, 1998.
32. Clark DB, Bukstein OG: Psychopathology in adolescent alcohol abuse and dependence.
Alcohol Health & Research World, 22:117-121, 1998.
33. Kolko D, Bukstein OG, Barron J: Methylphenidate and behavior modification in children with
ADHD and comorbid ODD or CD: Main and incremental effects across settings. J Am Acad
Child Adolesc Psychiatry, 38:578-586, 1999.
34. Bukstein OG: Disruptive behavior disorders and substance use disorders in adolescents.
Journal of Psychoactive Drugs, 32:67-80, 2000.
35. Martin CS, Pollock NK, Bukstein OG, Lynch KG: Inter-rater reliability of the SCID alcohol
and substance use disorders section among adolescents. Drug Alcohol Depend, 59:173-176,
2000.
36. Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, Simpson S, Shapiro
S, Bukstein OG, Myack C: Behavioral versus behavioral and pharmacological treatment in
ADHD children attending a summer treatment program. J Abn Child Psychology, 28:507-526,
2000.
37. Swanson J, Greenhill L, Pelham W, Wilen T, Wolraich M, Abikoff H, Atkins M, August G,
Biederman J, Bukstein OG, et al.: Initiating Concerta (OROS methylphenidate) q d in
children with attention deficit hyperactivity disorder. J Clin Research, 3:59-76, 2000.
38. Cornelius JR, Bukstein OG, Birmaher B, Salloum IM, Lynch K, Pollack NK, Gershon S,
Clark D: Fluoxetine in adolescents with major depression and an alcohol use disorder; an open
label trial. Addict Behav, 26:735-739, 2001.
39. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold E., Abikoff
HB, Bukstein OG, et al.: Impairment and Deportment responses to different methylphenidate
doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry,
40:180-187, 2001.
40. Viltiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, et al.:
Methylphenidate dosage for children with ADHD over time under controlled conditions:
Lessons from the MTA. J Am Acad Child Adolesc Psychiatry, 40:188-196, 2001
41. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M,
McBurnett K, Bukstein O, August G on behalf of the Concerta Study Group: Randomized,
controlled trial of OROS methylphenidate once a day in children with Attention-
Deficit/Hyperactivity Disorder. Pediatrics, 108:883-892, 2001.
42. McClellan J, Werry J, Bernet W, Arnold V, Beitchman J, Benson S, Bukstein O, Kinlan J,
Rue D, Shaw J: Practice parameter for the assessment and treatment of children and
adolescents with schizophrenia. J American Acad Child Adolesc Psychiatry, 40(Suppl):4S-
23S, 2001.
43. Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy E M, Greiner AR, Altenderfer L,
Baron-Myak C: Dose-response effects of methylphenidate on ecologically valid measures of
academic performance and classroom behavior in adolescents with ADHD. Exp Clin
Psychopharmacol, 9:163-175, 2001.
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 20 of 32
Revised November 16, 2013
13
44. Cornelius JR, Clark DB, Salloum IM, Bukstein OG, Kelly TM: Management of suicidal
behavior in alcoholism. Clinical Neuroscience Research, 1:381-386, 2001.
45. Molina BSG., Bukstein OG, Lynch K: Attention-Deficit/Hyperactivity Disorder and Conduct
Disorder symptomatology in adolescents with Alcohol Use Disorder. Psychol Addict Behav,
16:161-164, 2002.
46. Clark DB, Bukstein OG, Cornelius J: Alcohol use disorders in adolescents. Pediatr Drugs,
4:493-502, 2002.
47. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge TR, Clark DB: Psychiatric
disorders among older adolescents treated in emergency departments on weekends: A
comparison with a matched community sample. J Studies Alcohol, 64:616-622, 2003.
48. Clark DB, Wood DS, Cornelius JR, Bukstein OG, Martin CS: Clinical Practices in the
Pharmacological treatment of Comorbid Psychopathology in Adolescents with Alcohol Use
Disorders. J Subst Abuse Treat, 25:293-295, 2003.
49. Cornelius JR, Bukstein OG, Salloum IM, Kelly TM, Wood DS, Clark DB: Fluoxetine in
depressed AUD adolescents: A one-year follow-up evaluation. J Child Adolesc
Psychopharmacol, 14:33-38, 2004.
50. Cornelius JR, Clark DB, Salloum IM, Bukstein OG, Kelly TM: Interventions in Suicidal
Alcoholics. Alcohol Clin Exp Res, 28(5 Suppl):1S-8S, 2004.
51. Cornelius JR, Maisto SA, Martin CS, Bukstein OG, Salloum IM, Daley DC, Wood DS, Clark
DB: Major depression associated with earlier alcohol relapse in treated teens with AUD.
Addict Behav, 26:1035-1038, 2004.
52. Bukstein OG: Satisfaction with Treatment for Attention-Deficit/Hyperactivity Disorder.
American Journal of Managed Care, 10:S107-116, 2004.
53. Kelly TM, Bukstein OG: Evaluation and Treatment of Substance Use Problems among
Adolescents in Emergency Departments. Clin Ped Emerg Med, 5:164-172, 2004
54. Bukstein OG, Winters K: Salient variables for treatment research of adolescent alcohol and
other substance use disorders. Addiction, 99 (Suppl):23S–37S, 2004.
55. Bukstein OG, Trunzo AC: Alcohol use disorders in adolescents. Minerva Pediatr, 57:7-20,
2005.
56. Chacko A, Pelham WE, Gnagy E, Greiner A, Vallano G, Bukstein O, Rancurello M: Stimulant
Medication Effects in a Summer Treatment Program Among Young Children With Attention-
Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 44:249-257, 2005.
57. American Academy of Child and Adolescent Psychiatry, Primary author: Bukstein OG:
Practice parameters for the assessment and treatment of children and adolescents with
substance use disorders. J Am Acad Child Adol Psychiatry, 44:609-621, 2005.
58. Cornelius JR, Clark DB, Bukstein OG, Kelly TM, Salloum IM, Wood DS: Fluoxetine in
adolescents with comorbid major depression and an alcohol use disorder: A 3-year follow-up
study. Addict Behav, 30:807-814, 2005.
59. Bukstein OG, Cornelius J, Trunzo AC, Kelly TM, Wood DS. Clinical Predictors of Treatment
in a Population of Adolescents with Alcohol Use Disorders. Addict Behav, 30:1663-1673,
2005.
60. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge, TR, Kinnane JM: Alcohol use
disorder symptoms and risk-taking behavior as predictors of alcohol-related medical events
among young adults treated in emergency departments. Addict Behav, 30:1674-1689, 2005.
61. Cornelius JR, Clark DB, Bukstein OG, Birmaher B, Salloum IM, Brown SA: Acute phase and
five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid
substance use disorder: A review. Addict Behav, 30:1824-1833, 2005.
62. Galanter CA, Pager DL, Davies M, Li W, Carlson GA, Abikoff, HB, Arnold LE, Bukstein
OG, Pelham W, Elliot GR, Hinshaw S, Epstein JN, Wells K, Hechtman L, Newcorn JH,
Greenhill L, Wigal T, Swanson JM, Jensen PS: ADHD and manic symptoms: Diagnostic and
treatment implications, Clinical Neuroscience Research, 5:283-295, 2005.
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 21 of 32
Revised November 16, 2013
14
63. Bukstein OG, Cornelius J, Kelly TM, Wood DS: Bipolar Disorder in a Population of
Adolescents with Alcohol Use Disorders. Journal of Dual Disorders, 2:59-72, 2005.
64. Wilens T, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners
CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P,
Bloom L, Zimmerman BA, Gu J, Cooper K, Lynch JM: A Multisite, Controlled Trial of
OROS® Methylphenidate (CONCERTA®) in the Treatment of Adolescents with Attention-
Deficit/Hyperactivity Disorder. Archives of Pediatrics and Adolescent Medicine, 160:82-90,
2006.
65. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M: Once-
daily OROS methylphenidate is safe and well tolerated in adolescents with attention-
deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 16(2):351–356, 2006.
66. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Pettegrew JW,
Keshavan MS, Bukstein OG: Regionally specific alterations in membrane phospholipids in
children with ADHD: An in vivo31
P spectroscopy study. Psychiatry Research: Neuroimaging,
148:217–221, 2006.
67. Szobot C, Rohde L, Bukstein O, Molina B, Martins C, Ruaro P, Pechansky F: Is Attention-
Deficit/Hyperactivity Disorder associated with illicit Substance Use Disorders in male
adolescents? A community-based case-control study. Addiction, 102:1122–1130, 2007.
68. March JS, Szatmari P, Bukstein O, Chrisman A, Kondo D, Hamilton JD, Kremer C,
Kratochvil CJ: AACAP 2005 Research Forum: Speeding The Adoption Of Evidence-Based
Practice In Pediatric Psychiatry. J Am Acad Child Adolesc Psychiatry, 46:1098-1110, 2007.
69. Kolko DJ, Baumann BL, Bukstein OG, Brown, EJ: Internalizing symptoms and affective
reactivity in relation to the severity of aggression in clinically referred, behavior-disordered
children. Journal of Child and Family Studies, 16:745-759, 2007.
70. Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDermott MP, The CAT
Study Team: Clonidine for Attention-Deficit/Hyperactivity Disorder: I. Efficacy and
tolerability outcomes. J Am Acad Child Adolesc Psychiatry, 47:180-188, 2008.
71. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, Palumbo D,
Harris P, Sallee FR, The CAT Study Team: Clonidine for Attention-Deficit/Hyperactivity
Disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc
Psychiatry, 47:189-198, 2008.
72. Kolko DJ, Dorn LD, Bukstein OG, Burke J: Clinically Referred ODD children with or without
CD and healthy controls: Comparisons across contextual domains. Journal of Child and Family
Studies, Online First™, 2008.
73. Szobot CM, Bukstein O: Attention deficit hyperactivity disorder and substance use disorders.
Child Adolesc Psychiatric Clin N Am, 17:309-323, 2008.
74. Szobot CM, Rohde LA, Katz B, Ruaro P, Schaefer T. Walcher M, Bukstein O, Pechansky F:
A randomized crossover clinical study showing that methylphenidate-SODAS improves
Attention-Deficit/ Hyperactivity Disorder symptoms in adolescents with Substance Use
Disorder: a randomized crossover clinical trial. The Brazilian Journal of Medical and
Biological Research, 41: 250-257, 2008.
75. Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD: A
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Methylphenidate
Transdermal System in Pediatric Patients with ADHD. J Clin Psychiatry, 69:149–159, 2008.
76. Marshal MP, Friedman MS, Stall R, King KM, Miles J, Gold MA, Bukstein OG, Morse JQ:
Sexual orientation and adolescent substance use: A meta-analysis and methodological review.
Addiction, 103:546–556, 2008
77. Cornelius JR, Bukstein OG, Clark DB, Matta JK, Salloum IM, Wood DS: Fluoxetine Trial for
the Cannabis-Related Symptoms of Comorbid Adolescents. Journal of Drug Addiction,
Education and Eradication, 3:223-228, 2008.
78. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Keshavan MS, Bukstein
OG, Pettegrew JW: Evidence of Developmental Alterations in Cortical and Subcortical Regions
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 22 of 32
Revised November 16, 2013
15
of Children With Attention-Deficit/Hyperactivity Disorder: A Multivoxel In Vivo Phosphorus
31 Spectroscopy Study. Arch Gen Psychiatry, 65:1419-1428, 2008
79. Molina BSG, Flory K, Bukstein OG, Greiner AR, Baker JL, Krug V, Evans S: Feasibility and
preliminary efficacy of an after school program for middle schoolers with ADHD: A
randomized trial in a large public middle school. J Atten Disord, 12:207 – 217, 2008.
80. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL: Effects of Once-
Daily Oral and Transdermal Methylphenidate on Sleep Behavior of Children with ADHD. J
Atten Disord, 12:308-315, 2009.
81. Dorn LD, Kolko DJ, Susman EJ, Huang B, Stein H, Music E, BuksteinOG: Salivary gonadal
and adrenal hormone differences in boys and girls with and without disruptive behavior
disorders: Contextual variants. Biological Psychology, 81:31-39, 2009.
82. Kolko DJ, Dorn LD, Bukstein OG, Pardini J, Holden EA, Hart J: Community vs. Clinic-Based
Modular Treatment of Children with Early-Onset ODD or CD: A Clinical Trial with 3-Year
Follow-Up. J Abnorm Child Psychol, 37:591–609, 2009.
83. Brent DA, Greenhill LL, Compton S, Emslie G, Wells K, Walkup JT, Vitiello B, Bukstein O,
Stanley B, Posner K, Kennard BD, Cwik MF, Wagner A, Coffey B, March JS, Riddle M,
Goldstein T, Curry J, Barnett S, Capasso L, Zelazny J, Hughes J, Shen SA, Gugga SS, Tuner
JB: The Treatment of Adolescent Suicide Attempters Study (TASA): Predictors of suicide
events in an open treatment trial. J Am Acad Child Adolesc Psychiatry, 48:987-996, 2009.
84. Vitiello B, Brent DA, Greenhill LL, Emslie G, Wells K, Walkup JT, Stanley B, Bukstein O,
Kennard BD, Compton S, Coffey B, Cwik MF, Posner K, Wagner A, March JS, Riddle M,
Goldstein T, Curry J, Capasso L, Mayes T, Shen SA, Gugga SS, Turner JB, Barnett S, Zelazny
J: Depressive symptoms and clinical status during the Treatment of Adolescent Suicide
Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry, 48:997-1004, 2009.
83. Kelly TM, Donovan JE, Chung T, Bukstein OG, Cornelius JR: Brief Screens for Detecting
Alcohol Use Disorder Among 18-20 Year Old Young Adults in Emergency Departments:
Comparing AUDIT-C, CRAFFT, RAPS4-QF, FAST, RUFT-Cut, and DSM-IV 2-Item Scale.
Addictive Behaviors, 34: 668-674, 2009.
84. Cornelius JR, Bukstein OG, Wood DS, Kirisci L, Douaihy A, Clark DB: Double-Blind
placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an
alcohol use disorder. Addictive Behaviors, 34:905-909, 2009.
85. Bukstein O, Arnold LE, Landgraf J, Hodgkins P. Does switching from oral extended-release
methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life
and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child
Adolesc Psychiatry Ment Health, 3(1):39-51, 2009.
86. Cannon M, Pelham WH, Salee, FR, Palumbo DR, Bukstein, O, Daviss WB Effects of
clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity
disorder. Journal of Child & Adolescent Psychopharmacology. 19(5):511-7, 2009.
86. Arnold L, Bozzolo D, Hodgkins P, McKay M, Beckett-Thurman L, Greenbaum M, Bukstein O,
Patel A. Switching from oral extended-release methylphenidate to the methylphenidate
transdermal system: continued attention-deficit/hyperactivity disorder symptom control and
tolerability after abrupt conversion. Current Medical Research & Opinion. 26(1):129-137, 2010.
87. Goldstein BI, Bukstein OG: Comorbid Substance Use Disorders among Youth with Bipolar
Disorder: Opportunities for Early Identification and Prevention. J Clin Psychiatry.
Mar;71(3):348-58, 2010.
88. Bukstein OG, Horner MS. Management of the adolescent with substance use disorders and
comorbid psychopathology. Child Adolesc Psychiatr Clin N Am. 19(3):609-23, 2010.
89. Findling RL. Wigal SB. Bukstein OG. Boellner SW. Abikoff HB, Turnbow JM. Civil R.
Long-term tolerability of the methylphenidate transdermal system in pediatric attention-
deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled,
phase III extension of four clinical trials. Clinical Therapeutics. 31(8):1844-55, 2009.
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 23 of 32
Revised November 16, 2013
16
90. Jack R. Cornelius, JR, Bukstein OG, Douaihy AB, Clark, DB, Chung TA, Daley DC, Wood
DS, Brown, SJ. Double-blind fluoxetine trial in comorbid MDD–CUD youth and young adults.
Drug and Alcohol Dependence 112 39–45, 2010.
91. Bukstein OG. Clinical practice guidelines for attention-deficit/hyperactivity disorder: a review.
Postgrad Med. 122(5):69-77, 2010.
92. Demidovich, M. Kolko, DJ, Bukstein, OG, Hart J, Journal of Child and Adolescent
Psychopharmacology 21: 57-66, 2011.
93. Farmer CA, Arnold LE, Bukstein OG, Findling RL, Gadow KD, Li X, Butter EM, Aman MG.
The Treatment of Severe Child Aggression (TOSCA) Study: Design Challenges. Child Adolesc
Psychiatry Ment Health 5(1): 36,
94. Cornelius JR, Douaihy A, Bukstein OG, Daley DC, Wood SD, Kelly TM, Salloum IM.
Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a
treatment trial of comorbid MDD/AUD adolescents. Addictive Behaviors. 36(8): 843-848, 2011.
95. Dorn LD, Kolko DJ, Shenk CE, Susman EJ, Bukstein O. Influence of treatment for disruptive
behavior disorders on adrenal and gonadal hormones in youth. Journal of Clinical Child and
Adolescent Psychology. 40(4): 562-571, 2011.
96. Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K,
Youcha S, A controlled trial of extended-release guanfacine and psychostimulants for attention-
deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 51(1):74-85, 2012.
97. Bukstein OG, Head J, Guanfacine ER for the treatment of adolescent attention-
deficit/hyperactivity disorder. Expert Opinion. Posted online on September 7, 2012.
(doi:10.1517/14656566.2012.721778)
98. Pelham WE, Meichenbaum D, Smith B, Sibley MH, Gnagy E, & Bukstein O. (in press). The
Effect of MPH on Parent-Directed Conflict Behavior in Adolescents with ADHD. Journal of
Attention Disorders.
99. Pearson DA, Santos CW, Aman MG, Arnold LE, Casat CD, Mansour R, Lane DM, Loveland KA,
Bukstein OG, Jerger SW, Factor P, Vanwoerden S, Perez E, & Cleveland LA (in press). Effects
of extended release methylphenidate treatment on ratings of ADHD and associated behavior in
children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent
Psychopharmacology, 23(5): 337-351 2013.
100. Pelham, W.E., Gnagy, E.M., Sibley, M.H., Kipp, H.L., Smith, B.H., Evans, S.W., & Bukstein, O.
(in press). Attributions and Perception of Methylphenidate Effects in Adolescents with ADHD.
Journal of Attention Disorders , doi: 10.1177/1087054713493320
101. Goldstein BI, Goldstein TR, Collinger KA, Axelson DA, Bukstein OG, Birmaher B, Millowiitz
DJ (in press) Treatment Development and Feasibility Study of Family-Focused Treatment for
Adolescents with Bipolar Disorder and Comorbid Substance Use Disorders Journal of Psychiatric
Practice.
102. Aman, M.G., Bukstein, O.G., Gadow, K.D., Arnold, L.E., Molina, B.S.G., McNamara, N.K., Rundberg-Rivera, V., Li, X., Kipp, H., Schneider, J., Butter, E.M., Baker, J., Sprafkin, J., Rice, R.R., Bangalore, S.S., Farmer, C.A., Austin, A.B., Buchan-Page, K.A., Arradaza, N.V., Hurt, E.A., Grondhuis, S.N., Findling, R.L. (In press). What does risperidone add to stimulant and parent training for severe aggression in child ADHD? Journal of the American Academy of Child and Adolescent Psychiatry.
2. Other Papers: Invited Articles:
1. Bukstein OG: Drug testing in schools: good practice or good politics? Random drug testing of
adolescent students sounds like good commonsense policy--but where's the evidence? Behavioral
Health Management, July, 2004.
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 24 of 32
Revised November 16, 2013
17
2. Bukstein OG: Dual Disorders in Adolescents (Editorial). Journal of Dual Disorders, 2:7-9,
2006.
3. Bukstein OG: Therapeutic challenges of attention-deficit hyperactivity disorder with substance
use disorders. Expert Review of Neurotherapeutics, 6:541-549, 2007.
4. Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML: Changes and challenges: Managing
ADHD in a fast-paced world. J Manag Car Pharm, 13(9 Suppl B):S2-S13; quiz:S14-S16, 2007.
5. Bukstein OG: Substance abuse in patients with Attention-Deficit/Hyperactivity Disorder. The
Medscape Journal of Medicine, 10(1), 2008.
6. Bukstein O: Substance use disorders in adolescents with attention-deficit/hyperactivity disorder.
Adolescent Medicine, 19, 242-53, 2008.
3. Abstracts
4. Books a. Complete books written
Bukstein OG: Adolescent substance abuse: Assessment, treatment and prevention perspectives.
Wiley, New York, 1995.
b. Books edited
Kaminer Y, Bukstein OG: Adolescent Substance Abuse: Psychiatric Comorbidity and High
Risk Behaviors. New York, NY. Routledge Mental Health, 2008.
c. Book chapters
5. Kaminer Y, Bukstein O: Inpatient Behavior Therapy for Dually Diagnosed Chemically
Dependent Adolescents. In, Van Hasselt VB & Kolko DJ (Eds.), Inpatient Behavior Therapy
for Children and Adolescents. (pp. 313-363). New York: Plenum Press, 1992.
6. Bukstein OG: Overview of pharmacological treatment. In, Van Hasselt VB& Hersen M
(Eds.), Handbook of Behavior Therapy and Pharmacotherapy for Children: A comparative
analysis. (pp. 13-32) Needham Heights, MA: Allyn and Bacon, 1993.
7. Bukstein OG, Van Hasselt, VB: Alcohol and drug abuse. In, Bellack AS & Hersen M
(Eds.), Handbook of Behavior Therapy in the Psychiatric Setting. pp 453-476 New York:
Plenum, 1993.
8. Bukstein OG: Substance abuse. In, Hersen M, Ammerman RT & Sisson LA (Eds.),
Handbook of Aggressive and Destructive Behavior in Psychiatric Patients. (pp. 445-468)
New York: Plenum Press, 1994.
9. Windle M, Shope JT, Bukstein OG: Alcohol use. In, DiClemente RJ, Hansen WB & Ponton
LE (Eds.), Handbook of Adolescent Health Risk Behavior. (pp. 115-159). New York:
Plenum Press, 1996.
10. Bukstein OG: The Medical History. In, Hersen M & Van Hasselt VB (Eds.), Basic
Interviewing: A Practical Guide for Counselors and Clinicians. (pp. 87-106). Hillsdale, NJ:
Lawrence Erlbaum Associates, 1998.
11. Bukstein OG, Tarter RE: Adolescent substance use disorders. In, McCracken J, (Ed.),
Textbook of Pediatric Neuropsychiatry. (pp. 595-616). Washington, DC: American
Psychiatric Press, 1998.
12. Kaminer Y, Bukstein OG: Adolescent substance abuse. In, Frances RJ & Miller SI (Eds.),
Clinical Textbook of Addictive Disorders (2nd ed.). (pp. 346-373). New York, NY: Guilford
Press, 1998.
13. Bukstein OG: Adolescent Substance Abuse. In, Sadock BJ & Sadock VA (Eds.),
Comprehensive Textbook of Psychiatry, (7th Edition). (pp. 2932-2938). Baltimore, MD:
Lippincott Williams & Wilkins, 1999.
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 25 of 32
Revised November 16, 2013
18
14. Bukstein OG: Substance Abuse. In, Haymean LL, Mahon MM & Turner JR (Eds.), Health
Behavior in childhood and Adolescence. (pp. 178-212) New York, NY: Springer Publishing
Co., 2002.
15. Bukstein OG, Kithas J: Pharmacologicsal Treatment of Substance Use Disorders. In,
Rosenberg, D.A., Davanzo, P.A., Gershon, S. Pharmacotherapy for Child and Adolescent
Psychaitric Disorders, 2nd Edition. (pp. 679-710). New York, NY: Marcal-Dekker, 2002.
16. Barkley, R….Bukstein, O.G… et al.: Consensus statement on ADHD. European Child and
Adolescent Psychiatry, 11(2):96-98, 2002.
17. Bukstein, O.G. Psychopharmacolgy of Disruptive Behavior Disorders In Essau, C.A. (Ed.)
Conduct and Oppositional Defiant Disorders. (pp. 319-358). Mahwah, New Jersey:
Lawrence Erlbaum, 2003.
18. Cornelius JR, Salloum IM, Bukstein OG, Clark DB: Psychaitric comorbidity: Implications
for treatment and clinical research. In, Soares JC, Gershon S (Eds.), Handbook of Medical
Psychiatry. (pp. 553-561). New York, NY: Marcal-Dekker, 2003.
19. Cornelius JR, Bukstein OG, Salloum IM, Clark DB: Alcohol and psychiatric
comorbidity. In, Galanter M (Ed), Recent Developments in Alcoholism: Research on
Alcoholism Treatment (v. 16) (pp. 361-374). Norwell, MA: Kluwer Academic, 2005.
20. Bukstein OG, Cornelius JR: Psychopharmacology of adolescents with substance use
disorders: using diagnostic specific treatments. In, Liddle HA, Rowe CL (Eds.), Adolescent
Substance Abuse: Research and Clinical Advances. (pp. 241-263). Cambridge, UK;
Cambridge University Press, 2005.
21. Bukstein OG, Tarter R.: Substance use disorders. In, Coffey CE, Brumback RA(Eds),
Pediatric Neuropsychiatry. (pp. 321-341). Philadelphia, PA: Lippincott Williams &
Williams, 2005.
22. Bukstein OG, Lutka-Fedor T: Principles of assessment for adolescents with substance use
disorders. In, Gilvarry E, McArdle P (Eds.), Alcohol, Drugs and Young People. (pp. 127-
135). Newcastle Upon Tyne, England: Mac Keith Press, 2007.
23. Bukstein OG, Lutka-Fedor T: Assessment instruments and outcome measurement. In
Gilvarry E, McArdle P (Eds.), Alcohol, Drugs and Young People. (pp. 136-149). Newcastle
Upon Tyne: England: Mac Keith Press, 2007.
24. Szobot, Claudia M and Bukstein, O. Substance Use Disorders in Adolescence. In: Advances
in Biological Psychiatry – Biological Child Psychiatry. Basel:Karger, 24: 166-180, 2008.
25. Bukstein, O: Adolescent Substance Abuse. In: Sadock BJ, Sadock VA, Ruiz (Eds.),
Comprehensive Textbook of Psychiatry, 9th Edition. (pp3818-3813). Philadelphia: Wolters
Kluwer/Lippincott Williams & Wilkins, 2009.
26. Bukstein OG, Deas D: Substance Abuse and Addictions. In: Dulcan MK (Ed.), Dulcan’s
Textbook of Child and Adolescent Psychiatry. ((pp. 241-260). Washington, DC: American
Psychiatric Press, INC, 2009.
27. Bukstein OG. Attention Deficit Hyperactivity Disorder and Substance Use Disorders. In
Stanford C and Tannock R (eds.), Behavioral Neuroscience of Attention Deficit
Hyperactivity Disorder and Its Treatment, Current Topics in Behavioral Neurosciences
(pp146-172). Berlin Heidelberg: Springer‐Verlag 2011.
28. Cornelius JR, Bukstein OG, Clark DB, Matta JK, Salloum IM: Fluoxetine trial for the
cannabis-related symptoms of comorbid adolescents. In, Walcott TA (Ed.), Drug and
Alcohol Abuse Research Focus. Hauppauge NY; Nova Science Publishers, in press
29. Other Non-refereed Publications:
Walter, HJ, Bukstein, OG: Clinical practice guidelines: Drs. Walter and Bukstein reply. J Am
Acad Child Adolesc Psychiatry, 46:940-942, 2007.
Bukstein, OG Taking Note of Over-the-Counter Remedies for Adolescents with Cannabis
Dependence. Am J. Psychiatry, 169:771-773, 2012.
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 26 of 32
Revised November 16, 2013
19
III. Teaching Information
A. Didactic course work
1. Courses taught at University of Texas: (number of annual hours)
a. Disruptive Behaviors (including ADHD, Substance Use Disorders, QAggressive
behavior; 12 hours 10/10-6/13
b. Developmental neuroscience: 10 hours 10/10-7/13
c. Adult ADHD: 2 hours, 10/10-7/13
d. Miscellaneous child therapies: CBT, PMT: 5 hours 10/10-7/13
e. Motivational Interviewing (Adults and Adolescents): 12 hours 12/12-4/13
2. Courses taught at University of Pittsburgh
1. Annual In-service Presentations to Staff at Western Psychiatric Institute and Clinic on
Adolescent Substance abuse, Attention-Deficit Hyperactivity Disorder and other
Disruptive Behavior Disorders and Diagnosis of Childhood Disorders 1988-2010
2. Pediatric Psychopharmacology, lecture for Dr. Susan Campbell’s undergraduate child
psychopathology class 1993
3. Annual Lecture, Aggressive Behavior in children and Adolescents (PGY-III) 1993-2003
4. Faculty Facilitator, Faculty and Students Together (FAST) Program 1994-1996
5. Semi-annual lecture on Assessment of Children and Adolescents (PGY-I) 1994-2005
6. Clinical Neuroscience Clerkship, PBL: ADHD1995-2004
7. Children’s Hospital of Pittsburgh, Adolescent Clinic noon conference series, annual
lectures on ADHD and adolescent substance use disorders 1996-2010
8. Faculty Facilitator, Introduction to Being a Physician Course 1997-1998
9. Faculty Facilitator, Human Behavior Course - MS-II, Problem-Based Learning 1998-
2010
10. Organizer and presenter, Disruptive Behavior Disorders and Substance Use Disorders
Course (PGY-IV): ADHD, pharmacologic treatments, and adolescent substance use
disorders 1998-2010
11. NIMH Undergraduate Research Fellowship Program: (5 hours/year) 2001-2010
12. Annual and semi-annual training to trainees, staff and junior faculty in Motivational
Interviewing: 10 hours/year, 2002-2010
m. Psychiatric Epidemiology & Alcohol Research Seminar, lecture, Comorbidity of
Substance Use and Disorders in Adolescents (3/14/03)
n. Psychiatric Epidemiology & Alcohol Research Seminar, lecture, Depression and Alcohol
use Disorders in Female Adolescents (12/9/05)
o. WPIC Wide Journal Club, discussant (3/31/06; 6/1/06; 2/8/07; 1/10/08) 2005-2008
Organizer and presenter, Adult ADHD Course for Psychiatry Residents (PGY-III)
p. Advanced Psychopharmacology Class (PGY-III): ADHD Medications 2007-2010
Children’s Hospital of Pittsburgh, Pediatric resident noon conference series (1/16/08)
B. Non-didactic Teaching
1. Teaching and supervision of medical students at all levels: (average 3 hours/week) 1983-
2013
2. Teaching and supervision of psychiatry, family practice residents and nurse practitioner
students (average 1 per month): 1988-2010
3. Specific Supervision of Medical Students (University of Pittsburgh):
1) Nicole Christian, University of Pittsburgh SOM, Mentor, Scholarly Project, ADHD in a
Detention Center Population 7/2005-6/2008
2) Patrick Mc Garry, University of Pittsburgh SOM, Mentor, Scholarly Project, Prevalence and
motives for illicit use of prescription stimulants among undergraduate students 6/2006-5/2009
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 27 of 32
Revised November 16, 2013
20
3) Brain Slater, summer fellowship, Compliance in Adolescent Intensive Outpatient Therapy for
Substance Use Disorders 6/2007-10/2007
4) Caroline Nguyen, University of Pittsburgh SOM, Mentor, Scholarly Project 6/2008 -12/2010
5) Yulia Proosaselts. University of Pittsburgh SOM, Mentor, Scholarly Project 6/2010-8/2010
Other (University of Texas)
Angela Nash, UTHSC-H SON. Mentor, Doctoral dissertation 4/2011-present
4. SPONSORSHIP OF POSTDOCTORAL FELLOWS
a. Psychiatric Residents/ Fellows (Western Psychiatric Institute and Clinic):
1) Theresa Lutka-Fedor, Principles of Assessment for Adolescents with SUDs 7/2004-6/2005
2) Abigail Schlesinger, Tiffany Franchione, New Castle Youth Dev’ment Center 7/2004-6/2006
3) Mark Demidovich, Medication Refusal in ODD or CD Children with Comorbid ADHD:
Medication History and Clinical Correlates 7/2005-6/2009
4) Susan Morine, Treatment for Adolescent Substance Use Disorders 7/2006-7/2009
b. Faculty (Junior) and Other Post-Doctoral:
1) W. Burle Daviss, M.D. ADHD and Depressive Disorders in Children and
Adolescents 6/2000-6/2006
2) Tad Gorske, Ph.D. Effects of Cognitive Test Feedback on Patient Adherence 6/2004-
7/2008
3) Jeffrey Burke, Ph.D. Parental Help-seeking for Children’s Disruptive Behavior
9/2005-10/2010
4) Claudia Szobot, MD, postdoctoral fellow supported by her home institution, Center
for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal
University of Rio Grande do Sul, Brazil 6/2006-12/2009
5) Ben Goldstein, M.D. Family focused treatment for adolescents with bipolar disorder
and substance use disorders 6/2006-10/2009
6) Abigail Schlesinger, M.D., Services for ADHD in Primary Care 6/2006-7/2008
7) Srihari Bangelore, M.D., Frontal lobe Deficits in Children 6/2009-10/2012
C. Lectures: (include location, title of presentation, dates)
Evaluation of Adopted Children. Grand Rounds, Western Psychiatric Institute and Clinic
January 10, 1986
Depression and Substance Abuse. D'ART Conference, Pittsburgh, PA December 15,
1988
Dual-Diagnosis: Depression and Substance Abuse. Presentation and workshop, Office of
Education and Regional Programming (OERP), Washington, PA March 9, 1989
Genetics and Scientific Update in Diagnosis '89. Conference, Allegheny County
Medical Society, Pittsburgh, PA October 13, 1990
Administrative Issues in a Dual-Diagnosis Program, Grand Rounds, Department of
Psychiatry, West Virginia University January 26, 1990
Dual Diagnosis in Adolescents, Office of Education and Regional Programming (OERP):
Western Pennsylvania Regional Teleconference February 7, 1990
Adolescent Substance Abuse: Assessment and Treatment, Workshop, Annual
Conference for Services for Teens at Risk (STAR), Pittsburgh, PA March 16,
1990
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 28 of 32
Revised November 16, 2013
21
Dual Diagnosis in Adolescents, Office of Education and Regional Programming, Butler,
PA November 8, 1991
Dual Diagnosis in Adolescents, Office of Education and Regional Programming,
Western Psychiatric Institute and Clinic, Greensburg, PA December 11, 1991
Dual Diagnosis in Adolescents, Workshop, Youth Development Center, New Castle, PA
February 26, 1992 November 1, 1994
The Adolescent MISA Consumer. Pennsylvania Child/Adolescent Intensive Case
Management Training, State College, PA December 2, 1994
Disruptive Behavior Disorders: DSM-IV Update Teleconference, Office of Educational
and Regional Programming (OERP) January 11, 1995
Bullying, Counselor Conference, Allegheny Intermediate Unit, Pittsburgh, PA January
13, 1995
Dual Diagnosis in Adolescents, Office of Education and Regional Programming (OERP):
Western Pennsylvania Regional Teleconference March 1, 1995
Emergency Services for Children and Adolescents, Workshop at Conference:
"Emergency Psychiatry: Current Practice, Future Directions," Pittsburgh, PA
September 15, 1995
Mood and Conduct Disorders in Delinquent Youth, Youth Development Center, New
Castle, PA May 13, 1996
Psychopharmacology for Detained Youth, Juvenile Detention Center Association of
Pennsylvania, State College, PA May 23, 1996
Attention-Deficit Hyperactivity Disorder. Annual Meeting of the Pennsylvania
Association for Physicians Assistants, Pittsburgh, PA October 12, 1996
Mental Health Problems of Delinquents Office of Education and Regional Programming
(WPIC), St. Mary's, PA May 8, 1998
Mental health and Juvenile Justice May 8, 1998
Mental Health and Delinquency, Trouble Youth Conference, WPIC Office of
Education and Regional Programming (OERP), Moon, PA April 29, 1999
Troubled Youth: How Can the Profesisonal Help. Office of Education and Regional
Programing (OERP). Pittsburgh, PA April 29, 1999
Adolescent Treatment Update, Dual Diagnosis: 10 Years of Progress Conference, Center
for Psychiatry and Chemical Dependency Services, Pittsburgh, PA May 21, 1999
Attention Deficit Hyperactivity Disorder, Excellence in Mental Health in Schools
Conference, Carlisle, PA May 21, 2000
Psychopharmacology for Detained Youth, Juvenile Detention Center Association of
Pennsylvania Annual Meeting, State College, PA October 12, 2000
Current Issues in Attention Deficit Hyperactivity Disorder, Grand Rounds, Department
of Pediatrics, Mercy Hospital, Pittsburgh, PA November 14, 2000
Attention Deficit Hyperactivity and Substance Use Disorders, Grand Rounds,
Department of Psychiatry, Allegheny General Hospital, Pittsburgh, PA January
18, 2001
MISA in Adolescents, Office of Education and Regional Programing (OERP)
videoconference January 24, 2001
Psychopharmacology of Substance Use Disorders in Adolescents, Western Psychiatric
Institute and Clinic, Pittsburgh, PA January 26, 2001
The Assessment and Treatment of ADHD, Office of Education and Regional Programing
(OERP), New Castle, PA May 11, 2001
New Directions for Adolescent Substance Abuse. Office of Education and Regional
Programing (OERP). Hamarville, PA March 23, 2004
ADHD in Adults, Grand Rounds, Department of Psychiatry, Allegheny General
Hospital, Pittsburgh, PA April 22, 2004
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 29 of 32
Revised November 16, 2013
22
ADHD in Adults, Update in Internal Medicine, UPMC, Pittsburgh, PA November 19,
2004
ADHD in Adults, WPIC Staff Development December 2, 2004
Student Services Update: Substance Abuse and Psychaitric Issues – Ask the
Experts. Office of Education and Regional Programing (OERP), Pittsburgh, PA
January 31, 2006
Allegheny County DUI workshop; Risk Factors and Assessment of Adolescents with
alcohol Problems April 11, 2006
ADHD in Adults, Office of Education and Regional Programing (OERP), Mayville Sate
Hsopital, Pittsburgh, PA May 18, 2006
High School SAP Update, Diocese of Pittsburgh, Pittsburgh, PA June 27, 2006
Self-Injurious Behaviors and Adolescents, The Allegheny-Kiski Health
Foundation, New Kensington, PA November 15, 2006
ADHD in a Juvenile Detention Center Allegheny County Juvenile Court,
Monroeville, PA November 29, 2006
Adult ADHD, Office of Education and Regional Programing (OERP) Videoconference
January 17, 2007
Best practices for Integrating Treatment and Support for Adolescents with Co-Occurring
Disorders. Office of Education and Regional Programing (OERP), Monaca, PA
November 30, 2007
Treating ADHD and Substance Abuse with Adolescents. West Virginia Addiction
Training Institute, Morgantown, WV June 9, 2009
Comorbidity with Substance Abusing Adolescents West Virginia Addiction Training
Institute, Morgantown, WV June 9, 2009
IV. Medical & Service Information
A. Patient care responsibilities – University of Texas
1. UT Psychiatry Outpatient Services 11/10-6/13
2. South Region Collaborative outpatient serves 10/11-6/13
3. Children’s Assessment Center Outpatient services 4/11-6/13
4. Harris County Psychiatric Center Residential Treatment Program 7/11-6/12
B. Service to the Community
Task Force/Advisory Committee for Drug and Alcohol Abuse Training, Commonwealth
of Pennsylvania 1990 - 1991
Pro Bono Mental Health Project, Pittsburgh Women’s Shelter – Volunteer 1991-93
Member, Psychiatry Faculty-Medical Student Mentor Program 1996-Present
President, Pittsburgh Regional Organization of Child and Adolescent Psychiatry 2000-
2003
Substance Abuse Panel chair, the Health, Mental Health and Safety Guidelines for
Schools Project, sponsored by the American Academy of Pediatrics and the
National Association of School Nurses 2000-2004
Allegheny County Children’s Cabinet, Subcommittee on Mental Health and Juvenile
Justice 2001-2003
Member, Juvenile Detention Centers of Pennsylvania (JDCAP) Mental Health
Advisory Committee 2001-Present
Member, Allegheny County Public Psychiatry Advisory Group 2002-Present
Judge: “When Not to Keep a Secret” National High School Essay Contest,
Pennsylvania Psychiatric Society 2002
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 30 of 32
Revised November 16, 2013
23
Work Group on Services for Youth with Substance Abuse or Co-occurring Disorders,
Bureau of Children's Services – OMHSAS, Commonwealth of Pennsylvania
2004-2006
Consultation:
Child and Adolescent Psychiatric Evaluations and Consultation to Turtle Creek Valley
Mental Health/Mental Retardation Center, PA 1986-1988
Consultation to Administrative and Clinical Staff, Fayette County
Mental Health/Mental Retardation Program, Uniontown, PA 1986-1987
Emergency Outreach Program: screening students suicide(s) at local schools, Services
for Teens at Risk (STAR), Western Psychiatric Institute and Clinic1987-1992
Psychiatric Consultant, University of Pittsburgh Student Health Service and Student
Counseling Center 1988-1993
Psychiatric Consultant, Maximizing Adolescent Potentials (MAPS), School Of
Education, University of Pittsburgh 1988-Present
Psychiatric Consultant, Shuman Juvenile Detention Center of Allegheny County and
Allegheny County Juvenile Court 1993-Present
Consultant, Community Care Behavioral Health (CCBH), Pittsburgh, PA 1996-Present
U.S. Department of Health and Human Services, Center for Substance Abuse Prevention
(CSAP); training and consultation to various state and local agencies. 1996-
Present
External Consultant University of Miami, Howard Liddle (PI). Technology Transfer of
Multidimensional Family Therapy. Center for Treatment Research on Adolescent Drug
Abuse, University of Miami, Florida 2000-2003
Consultation to pharmaceutical companies (Alza Corp., McNeil Pediatrics, Shire
Pharmaceuticals, Cephalon) 2000-2007
Internal Consultant, University of Pittsburgh, Tammy Chung, (PI)
Diagnostic Criteria for Adolescent Alcohol Use Disorders, 2001-2006, NIAAA,
K01- Award. 2001-2006
National Institute on Drug Abuse (NIDA), Clinical Trials Network 2003-2005
University of Pittsburgh, Ralph Tarter (PI): Member Data and Safety Monitoring
Board (DSMB), The Center for Education and Drug Abuse Research (CEDAR)
(Funding: NIDA) 2004-2010
Internal Consultant, University of Pittsburgh, Tammy Chung, (PI)
Course of Alcohol and Drug Problems in Treated Teens, (Funding: NIAAA)
2004-2009
Internal Consultant, University of Pittsburgh, Tammy Chung, (PI) Mechanisms of Change
in Alcohol Treatment for Dually Diagnosed Youth 2007-Present
University of Pennsylvania, University of Pittsburgh: Chair, Data and Safety
Monitoring Board (DSMB), PA Adolescent Smoking Study (PASS Study) (funding: PA
State Tobacco Fund) 2007-Present
External Consultant, James Madison University, Steve Evans (PI): Treatment
Development for High School Students with ADHD (funding: NIMH) 2007-Present
University of Pittsburgh, Michael Marshall (PI): Understanding the Health and
Wellness of Pittsburgh Youth (funding: Pittsburgh Foundation) 2007-Present
Columbia University, Francis Levin (PI): Member of DSMB, Extended-Release
Amphetamine Salts for Adult ADHD and Cocaine Dependence (Funding: NIDA)
2008-Present
Faculty, Lone Star LEND (autism training center) at UTHSC-H (funding: NICHD) 2011-
Present
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 31 of 32
Revised November 16, 2013
24
C. Service to the University
1. UT Medical School At Houston-Department of Psychiatry & Behavioral Sciences
Chief/Director, Division of child and Adolescent Psychiatry 10/2010-7/2013 Member, Child/Adolescent Psychiatry Fellowship Committee 10/2010- 7/2013
Member, Department of Psychiatry Clinical Operations Committee 10/2010- 7/2013
Member, Department of Psychiatry Executive Committee 10/2010- 7/2013
Chair, Department of Psychiatry Grand Rounds Committee 10/2010- 6/2013
2. Service to the University of Pittsburgh
Vice President, Western Psychiatric Institute and Clinic House Staff Association 1985-
1986
Member of training faculty for Alcohol Research Training Program, Department of
Psychiatry, University of Pittsburgh. Dr. Marie Cornelius, Director. 1990-2010
Member of training faculty for Clinical Research Training in Child Psychiatry, Department
of Psychiatry, University of Pittsburgh. David A. Brent, MD, Director. 1990-2010
Member, Institutional Review Board, University of Pittsburgh 2003-2010
Vice-chair, Institutional Review Board, University of Pittsburgh 2007-2010
Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 32 of 32